Search This Blog

Wednesday, August 5, 2026

Recursion misses views

 

Recursion Pharmaceuticals posts Q2 loss of $0.25 per share on $7.7 million revenue, misses EPS and revenue estimates

  • Company disclosed in Q2 2026 SEC filing that Genentech advanced first neuroscience target under their collaboration.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)